Selected article for: "clinical treatment and health service"
Author: Liu, Danfei; Zhang, Tongyue; Wang, Yijun; Xia, Limin
Title: Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
  • Cord-id: hs62brjp
  • Document date: 2020_10_26
    • ID: hs62brjp
    Snippet: The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing the mortality and alleviating the tension of the health service system. Cytokine release syndrome (CRS) induced by elevated interleukin-6 was recognized to underscore the pathology of severe COVID-19 p
    Document: The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing the mortality and alleviating the tension of the health service system. Cytokine release syndrome (CRS) induced by elevated interleukin-6 was recognized to underscore the pathology of severe COVID-19 patients. Inhibiting CRS by agents suppressing IL-6 may relieve symptoms, shorten the hospital stay and reduce the need for oxygen therapy. Although evidence from randomized, double-blinded clinical trials is still lacking, the IL-6R inhibitor tocilizumab (TCZ) has shown some clinical benefits in the treatment of severe COVID-19 patients and have been included in clinical guidelines. In this review, we focused on the possible mechanisms of TCZ in the treatment of CRS and highlighted some significant considerations in the use of TCZ to treat COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • abnormal inflammation and acute ards respiratory distress syndrome: 1, 2, 3
    • abnormal inflammation and acute respiratory distress syndrome: 1, 2, 3, 4
    • abnormal inflammation and lung damage: 1, 2
    • abnormal inflammation and macrophage monocyte: 1, 2, 3
    • abnormal inflammatory and activation cascade: 1
    • abnormal inflammatory and acute ards respiratory distress syndrome: 1, 2, 3
    • abnormal inflammatory and acute phase: 1, 2, 3
    • abnormal inflammatory and acute respiratory distress syndrome: 1, 2, 3, 4
    • abnormal inflammatory and lung alveolar: 1, 2
    • abnormal inflammatory and lung damage: 1, 2